Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.– 26. **(Cancelled)**

27. **(Previously Presented)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

(a) administering, to a subject having a ras-activated neoplasm capable of developing drug resistance to a chemotherapeutic agent, an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

(b) administering to the subject an effective amount of the chemotherapeutic agent,

wherein the infection prevents the ras-activated neoplasm from developing drug resistance to the chemotherapeutic agent.

28. **(Previously Presented)** A method for preventing a ras-activated neoplasm in a subject from developing drug resistance to a chemotherapeutic agent, comprising:

(a) determining, in a subject having a ras-activated neoplasm, if the ras activated neoplasm includes ras-activated neoplastic cells that are refractory to a chemotherapeutic agent;

(b) administering to the subject an effective amount of reovirus under conditions which result in infection of the ras-activated neoplasm by the reovirus; and

(c) administering to the subject an effective amount of the chemotherapeutic agent,

wherein the infection prevents the ras-activated neoplasm from developing drug resistance to the chemotherapeutic agent.

29. – 30. (Cancelled)

31. **(Withdrawn)** A method of sensitizing a neoplastic cell to a chemotherapeutic agent, comprising: (a) administering to said neoplastic cell an effective amount of a virus, said virus being capable of selectively infecting neoplastic cells; and (b) administering an effective amount of the chemotherapeutic agent to said cell.

32. **(Withdrawn)** The method of claim 31 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.

33. **(Withdrawn)** A method of treating a subject with a chemotherapeutic agent wherein said subject harbors a proliferative disorder and neoplastic cells, comprising: (a) administering to the subject an effective amount of a virus under conditions that result in infection of the neoplastic

cells by the virus; and (b) administering an effective amount of the chemotherapeutic agent to said subject.

34. **(Withdrawn)** The method of claim 33 wherein the virus is selected from the group consisting of modified adenovirus, modified HSV, modified vaccinia virus, modified parapoxvirus orf virus, delNS1 virus, p53-expressing viruses, ONYX-015, Delta24, and vesicular stomatitis virus.

35. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

36. **(Previously Presented)** The method of claim 27 wherein the reovirus is a mammalian reovirus.

37. **(Previously Presented)** The method of claim 36 wherein the mammalian reovirus is a human reovirus.

38. **(Previously Presented)** The method of claim 37 wherein the human reovirus is a serotype 3 reovirus.

39. **(Previously Presented)** The method of claim 38 wherein the serotype 3 reovirus is a Dearing strain reovirus.

40. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered in multiple doses prior to administration of the chemotherapeutic agent.

41. **(Previously Presented)** The method of claim 27 wherein the reovirus is administered systemically.

42. **(Previously Presented)** The method of claim 27 wherein the chemotherapeutic agent is cisplatin.

43. **(Previously Presented)** The method of claim 27 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

44. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is selected from the group consisting of 5-fluorouracil, mitomycin C, methotrexate, hydroxyurea, cyclophosphamide, dacarbazine, mitoxantrone, anthracyclins, carboplatin, cisplatin, taxol, taxotere, tamoxifen, anti-estrogens, and interferons.

45. **(Previously Presented)** The method of claim 28 wherein the reovirus is a mammalian reovirus.

46. **(Previously Presented)** The method of claim 45 wherein the mammalian reovirus is a human reovirus.

47. **(Previously Presented)** The method of claim 46 wherein the human reovirus is a serotype 3 reovirus.

48. **(Previously Presented)** The method of claim 47 wherein the serotype 3 reovirus is a Dearing strain reovirus.

49. **(Previously Presented)** The method of claim 28 wherein the reovirus is administered systemically.

50. **(Previously Presented)** The method of claim 28 wherein the chemotherapeutic agent is cisplatin.

51. **(Previously Presented)** The method of claim 28 wherein the reovirus administration prevents the ras-activated neoplasm from developing drug resistance to a second chemotherapeutic agent.

52.-53. **(Cancelled)**

54. **(Previously Presented)** The method of claim 27, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

55. **(Previously Presented)** The method of claim 27, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

56. **(Previously Presented)** The method of claim 28, wherein the reovirus is administered prior to administration of the chemotherapeutic agent.

57. **(Previously Presented)** The method of claim 28, wherein the reovirus and the chemotherapeutic agent are administered concurrently.

58. **(Cancelled)**

59. **(Previously Presented)** The method of claim 27, wherein the ras activated neoplasm comprises ras-activated neoplastic cells that are refractory to the chemotherapeutic agent.